ֱ

Alzheimer's Trials Fail; Blood Test Predicts Tau; Neuroscience Moves to Bluesky

— News and commentary from the world of neurology and neuroscience

MedpageToday
Neuro Break over a computer rendering of neurons.

failed to reduce cognitive or functional decline in Alzheimer's disease patients in the ReThink-ALZ phase III trial, Cassava Sciences reported. The company stopped a second phase III study of the controversial drug.

The INVOKE-2 phase II trial of also did not slow clinical progression in people with early Alzheimer's disease, according to drug developer Alector.

Levels of were linked with verbal abilities in offspring; folate early in pregnancy was associated with improved outcomes. (JAMA Neurology)

A plasma phosphorylated tau-217 (ptau-217) test reliably in early Alzheimer's disease and could reduce reliance on tau PET scans. (Alzheimer's and Dementia)

Younger patients were disproportionately affected by of long COVID, regardless of acute COVID severity. (Annals of Neurology)

A wearable transcutaneous electrical nerve stimulation device eased , a pilot clinical trial showed. (Scientific Reports)

Long COVID , according to new research to be presented at the Radiological Society of North America (RSNA) annual meeting.

Another study to be presented at RSNA suggested concussions may in high school football players.

A mouse study identified a brain circuit in sexual rejection. (Neuron)

Daily neuroscience-related posts on the rose to average of 179 in mid-November -- up from an average of 15 daily posts in August -- as more researchers leave X. (The Transmitter)

Nine -- including actresses Selma Blair, Christina Applegate, and Jamie-Lynn Sigler -- shared their experiences with the disease. (People)

Former discussed how Parkinson's disease now affects his life. (TMZ Sports)

  • Judy George covers neurology and neuroscience news for ֱ, writing about brain aging, Alzheimer’s, dementia, MS, rare diseases, epilepsy, autism, headache, stroke, Parkinson’s, ALS, concussion, CTE, sleep, pain, and more.